



Corrigendum to “*In vitro* combinatorial anticancer effects of 5-fluorouracil and curcumin loaded *N,O*-carboxymethyl chitosan nanoparticles toward colon cancer and *in vivo* pharmacokinetic studies” [Eur. J. Pharmaceut. Biopharmaceut. 88 (2014) 238–251]



A. Anitha, Maya Sreeranganathan, Krishna Prasad Chennazhi, Vinoth-Kumar Lakshmanan, R. Jayakumar*

Amrita Centre for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences and Research Centre, Amrita Vishwa Vidyapeetham, Kochi, India

In the original manuscript, Fig. 3A was plotted wrong. The corrected Fig. 3A is presented below.

Similarly, in the original manuscript, Fig. 4A, the control bright field image for IEC 6 cells (upper panel) is incorrect. Instead of control

IEC 6 cell line image, we placed nanoparticles treated IEC 6 cell line image. Now we corrected Fig. 4A and presented below.

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.ejpb.2014.04.017>

* Corresponding author.

E-mail address: rjayakumar@aims.amrita.edu (R. Jayakumar).

<https://doi.org/10.1016/j.ejpb.2019.03.009>

Available online 14 March 2019

0939-6411/ © 2019 Elsevier B.V. All rights reserved.




Fig. 3. The hemocompatibility of 5-FU-N,O-CMC NPs and CUR-N,O-CMC NPs (A) hemolysis assay and (B) coagulation assays.




Fig. 4. The cellular uptake of Rhod 123-CUR-N,O-CMC NPs and Rhod 123-5-FU-N,O-CMC NPs by confocal imaging, where the upper and lower panel represents the bright field and fluorescent views of (A) IEC 6 and (B) HT 29 cells (6 h incubation).